SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Date of Report (Date of earliest event reported): August 28, 2012
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
Registrants telephone number, including area code: (301) 838-2500
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors and Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(e) Modification of Compensatory Arrangements With Executive Officers
On August 28, 2012, the Compensation Committee of Supernus Pharmaceuticals, Inc. (the Company) approved modifications of the base salaries of its executive officers, as follows:
The annual base salary of Jack A. Khattar, the Companys President and Chief Executive Officer, was increased from $432,786 to $450,000.
The annual base salary of Gregory S. Patrick, the Companys Vice President and Chief Financial Officer, was increased from $265,000 to $300,000.
The annual base salary of Stefan K.F. Schwabe, MD, Ph.D., the Companys Executive Vice President and Chief Medical Officer, was increased from $320,000 to $330,000.
The annual base salary of Padmanabh P. Bhatt, Ph.D., the Companys Senior Vice President, Intellectual Property and Chief Scientific Officer, was increased from $290,884 to $306,000.
The annual base salary of Jones W. Bryan, Ph.D., the Companys Vice President of Business Development, was increased from $223,364 to $250,000.
The annual base salary of Tami T. Martin, R.N., Esq., the Companys Vice President of Regulatory Affairs, was increased from $221,095 to $240,000.
These increases were the result of the Compensation Committees review subsequent to completion of the Companys recent initial public offering to ensure that the base salaries of the Companys executive officers are in line with the base salaries of executive officers of other public companies operating in its industry. These increases in annual base salary will become effective on September 1, 2012. All other terms and conditions of the Companys compensatory arrangements with these executive officers remain unchanged.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.